Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice

Radhika H. Muzumdar, Derek M. Huffman, John W. Calvert, Saurabh Jha, Yoni Weinberg, Lingguang Cui, Anjana Nemkal, Gil Atzmon, Laura Klein, Susheel Gundewar, Sang Yong Ji, Madhav Lavu, Benjamin L. Predmore, David J. Lefer

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objective-: Humanin (HN), an endogenous antiapoptotic peptide, has previously been shown to protect against Alzheimer's disease and a variety of cellular insults. We evaluated the effects of a potent analog of HN (HNG) in an in vivo murine model of myocardial ischemia and reperfusion. Methods and results-: Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion. HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion. The extent of myocardial infarction per area-at-risk was evaluated at 24 hours using Evans Blue dye and 2-3-5-triphenyl tetrazolium chloride staining. Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770). Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion. Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro. HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg. HNG therapy enhanced left ventricular ejection fraction and preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function. Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion. HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro. Conclusion-: These data show that HNG provides cardioprotection in a mouse model of myocardial ischemia and reperfusion potentially through activation of AMPK-endothelial nitric oxide synthase-mediated signaling and regulation of apoptotic factors. HNG may represent a novel agent for the treatment of acute myocardial infarction.

Original languageEnglish (US)
Pages (from-to)1940-1948
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume30
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Myocardial Reperfusion Injury
Myocardial Reperfusion
Reperfusion Injury
Reperfusion
Myocardial Ischemia
AMP-Activated Protein Kinases
Nitric Oxide Synthase Type III
Cardiac Myocytes
Myocardial Infarction
Phosphorylation
Apoptosis
bcl-2-Associated X Protein
Evans Blue
Daunorubicin
Coronary Occlusion
B-Cell Lymphoma
Left Ventricular Function
Stroke Volume
Echocardiography
Chlorides

Keywords

  • humanin
  • ischemia-reperfusion
  • myocardium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. / Muzumdar, Radhika H.; Huffman, Derek M.; Calvert, John W.; Jha, Saurabh; Weinberg, Yoni; Cui, Lingguang; Nemkal, Anjana; Atzmon, Gil; Klein, Laura; Gundewar, Susheel; Yong Ji, Sang; Lavu, Madhav; Predmore, Benjamin L.; Lefer, David J.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 30, No. 10, 10.2010, p. 1940-1948.

Research output: Contribution to journalArticle

Muzumdar, RH, Huffman, DM, Calvert, JW, Jha, S, Weinberg, Y, Cui, L, Nemkal, A, Atzmon, G, Klein, L, Gundewar, S, Yong Ji, S, Lavu, M, Predmore, BL & Lefer, DJ 2010, 'Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 10, pp. 1940-1948. https://doi.org/10.1161/ATVBAHA.110.205997
Muzumdar, Radhika H. ; Huffman, Derek M. ; Calvert, John W. ; Jha, Saurabh ; Weinberg, Yoni ; Cui, Lingguang ; Nemkal, Anjana ; Atzmon, Gil ; Klein, Laura ; Gundewar, Susheel ; Yong Ji, Sang ; Lavu, Madhav ; Predmore, Benjamin L. ; Lefer, David J. / Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2010 ; Vol. 30, No. 10. pp. 1940-1948.
@article{f95500b5c4b6493185caa44b3c7e1330,
title = "Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice",
abstract = "Objective-: Humanin (HN), an endogenous antiapoptotic peptide, has previously been shown to protect against Alzheimer's disease and a variety of cellular insults. We evaluated the effects of a potent analog of HN (HNG) in an in vivo murine model of myocardial ischemia and reperfusion. Methods and results-: Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion. HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion. The extent of myocardial infarction per area-at-risk was evaluated at 24 hours using Evans Blue dye and 2-3-5-triphenyl tetrazolium chloride staining. Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770). Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion. Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro. HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg. HNG therapy enhanced left ventricular ejection fraction and preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function. Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion. HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro. Conclusion-: These data show that HNG provides cardioprotection in a mouse model of myocardial ischemia and reperfusion potentially through activation of AMPK-endothelial nitric oxide synthase-mediated signaling and regulation of apoptotic factors. HNG may represent a novel agent for the treatment of acute myocardial infarction.",
keywords = "humanin, ischemia-reperfusion, myocardium",
author = "Muzumdar, {Radhika H.} and Huffman, {Derek M.} and Calvert, {John W.} and Saurabh Jha and Yoni Weinberg and Lingguang Cui and Anjana Nemkal and Gil Atzmon and Laura Klein and Susheel Gundewar and {Yong Ji}, Sang and Madhav Lavu and Predmore, {Benjamin L.} and Lefer, {David J.}",
year = "2010",
month = "10",
doi = "10.1161/ATVBAHA.110.205997",
language = "English (US)",
volume = "30",
pages = "1940--1948",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice

AU - Muzumdar, Radhika H.

AU - Huffman, Derek M.

AU - Calvert, John W.

AU - Jha, Saurabh

AU - Weinberg, Yoni

AU - Cui, Lingguang

AU - Nemkal, Anjana

AU - Atzmon, Gil

AU - Klein, Laura

AU - Gundewar, Susheel

AU - Yong Ji, Sang

AU - Lavu, Madhav

AU - Predmore, Benjamin L.

AU - Lefer, David J.

PY - 2010/10

Y1 - 2010/10

N2 - Objective-: Humanin (HN), an endogenous antiapoptotic peptide, has previously been shown to protect against Alzheimer's disease and a variety of cellular insults. We evaluated the effects of a potent analog of HN (HNG) in an in vivo murine model of myocardial ischemia and reperfusion. Methods and results-: Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion. HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion. The extent of myocardial infarction per area-at-risk was evaluated at 24 hours using Evans Blue dye and 2-3-5-triphenyl tetrazolium chloride staining. Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770). Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion. Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro. HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg. HNG therapy enhanced left ventricular ejection fraction and preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function. Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion. HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro. Conclusion-: These data show that HNG provides cardioprotection in a mouse model of myocardial ischemia and reperfusion potentially through activation of AMPK-endothelial nitric oxide synthase-mediated signaling and regulation of apoptotic factors. HNG may represent a novel agent for the treatment of acute myocardial infarction.

AB - Objective-: Humanin (HN), an endogenous antiapoptotic peptide, has previously been shown to protect against Alzheimer's disease and a variety of cellular insults. We evaluated the effects of a potent analog of HN (HNG) in an in vivo murine model of myocardial ischemia and reperfusion. Methods and results-: Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion. HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion. The extent of myocardial infarction per area-at-risk was evaluated at 24 hours using Evans Blue dye and 2-3-5-triphenyl tetrazolium chloride staining. Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770). Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion. Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro. HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg. HNG therapy enhanced left ventricular ejection fraction and preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function. Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion. HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro. Conclusion-: These data show that HNG provides cardioprotection in a mouse model of myocardial ischemia and reperfusion potentially through activation of AMPK-endothelial nitric oxide synthase-mediated signaling and regulation of apoptotic factors. HNG may represent a novel agent for the treatment of acute myocardial infarction.

KW - humanin

KW - ischemia-reperfusion

KW - myocardium

UR - http://www.scopus.com/inward/record.url?scp=77957714219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957714219&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.110.205997

DO - 10.1161/ATVBAHA.110.205997

M3 - Article

C2 - 20651283

AN - SCOPUS:77957714219

VL - 30

SP - 1940

EP - 1948

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 10

ER -